Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and <i>Mycoplasma hyopneumoniae</i> When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection

Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and <i>Mycoplasma hyopneumoniae</i> When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection

Four studies under preclinical and clinical conditions were performed to evaluate the efficacy of a new trivalent vaccine against Porcine circovirus 2 (PCV-2) infection. The product contained inactivated PCV-1/PCV-2a (cPCV-2a) and PCV-1/PCV-2b (cPCV-2b) chimeras, plus <i>M. hyopneumoniae</i...

Full description

Bibliographic Details
Main Authors: Patricia Pleguezuelos, Marina Sibila, Raúl Cuadrado-Matías, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera-Gracia, Lucas P. Taylor, Stasia Borowski, Gillian Saunders, Joaquim Segalés, Sergio López-Soria, Mònica Balasch
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Vaccines
Subjects:
swine
porcine circovirus 2
porcine circovirus 2-systemic disease
<i>Mycoplasma hyopneumoniae</i>
porcine respiratory disease complex
trivalent vaccine
Online Access:https://www.mdpi.com/2076-393X/10/8/1234

Internet

https://www.mdpi.com/2076-393X/10/8/1234

Similar Items